Bioventus Inc. (NYSE:BVS) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its holdings in shares of Bioventus Inc. (NYSE:BVS - Free Report) by 11.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 435,344 shares of the company's stock after acquiring an additional 45,182 shares during the period. Charles Schwab Investment Management Inc. owned about 0.54% of Bioventus worth $4,571,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Principal Financial Group Inc. grew its stake in Bioventus by 9.4% in the 4th quarter. Principal Financial Group Inc. now owns 19,228 shares of the company's stock worth $202,000 after acquiring an additional 1,652 shares during the period. Virtus Fund Advisers LLC purchased a new stake in shares of Bioventus in the third quarter valued at $42,000. Plato Investment Management Ltd acquired a new position in Bioventus in the fourth quarter valued at $38,000. Quest Partners LLC purchased a new position in Bioventus during the third quarter worth about $51,000. Finally, Quarry LP acquired a new stake in Bioventus in the 3rd quarter worth about $59,000. Hedge funds and other institutional investors own 62.94% of the company's stock.

Bioventus Trading Down 0.7 %

NYSE:BVS traded down $0.06 on Friday, hitting $9.03. 251,471 shares of the stock were exchanged, compared to its average volume of 431,244. The stock has a fifty day moving average of $10.07 and a 200-day moving average of $10.98. The stock has a market cap of $739.95 million, a PE ratio of -14.80 and a beta of 0.86. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. Bioventus Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.38.

Remove Ads

Insider Activity at Bioventus

In other news, CFO Mark Leonard Singleton sold 5,479 shares of the stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $9.79, for a total value of $53,639.41. Following the completion of the sale, the chief financial officer now owns 131,963 shares in the company, valued at approximately $1,291,917.77. This trade represents a 3.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Robert E. Claypoole sold 28,786 shares of the firm's stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $9.10, for a total value of $261,952.60. Following the sale, the chief executive officer now owns 64,964 shares in the company, valued at approximately $591,172.40. The trade was a 30.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 46,161 shares of company stock worth $436,364. Company insiders own 32.90% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on BVS. Canaccord Genuity Group reiterated a "buy" rating and set a $15.00 price objective on shares of Bioventus in a report on Monday, March 17th. JPMorgan Chase & Co. raised shares of Bioventus from an "underweight" rating to a "neutral" rating and increased their price target for the stock from $12.00 to $13.00 in a research note on Tuesday, December 17th.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.